BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Xiaodong Wang sold 31,028 shares of the company’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $364.79, for a total value of $11,318,704.12. Following the transaction, the insider owned 31,028 shares of the company’s stock, valued at approximately $11,318,704.12. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xiaodong Wang also recently made the following trade(s):
- On Tuesday, September 8th, Xiaodong Wang sold 38,287 shares of BeOne Medicines stock. The stock was sold at an average price of $349.10, for a total value of $13,365,991.70.
BeOne Medicines Stock Performance
ONC stock traded up $0.67 during mid-day trading on Wednesday, reaching $365.94. The company had a trading volume of 328,857 shares, compared to its average volume of 304,945. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $40.18 billion, a P/E ratio of 64.43 and a beta of 0.51. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The stock’s 50-day simple moving average is $351.75 and its two-hundred day simple moving average is $314.84.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in ONC. Steadtrust LLC increased its stake in shares of BeOne Medicines by 3.7% during the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after acquiring an additional 50 shares during the period. EverSource Wealth Advisors LLC lifted its position in BeOne Medicines by 16.4% in the first quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after purchasing an additional 52 shares during the period. Sequoia Financial Advisors LLC boosted its stake in BeOne Medicines by 4.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 1,628 shares of the company’s stock valued at $483,000 after purchasing an additional 65 shares in the last quarter. Parallel Advisors LLC boosted its stake in BeOne Medicines by 24.0% during the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after purchasing an additional 68 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of BeOne Medicines by 3.4% during the 1st quarter. Sanctuary Advisors LLC now owns 2,982 shares of the company’s stock valued at $886,000 after purchasing an additional 99 shares during the period. 48.55% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Weiss Ratings upgraded BeOne Medicines from a “sell (d-)” rating to a “hold (c+)” rating in a research report on Tuesday, September 22nd. Truist Financial boosted their price target on BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Finally, TD Cowen raised their price target on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $402.71.
About BeOne Medicines
BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.
Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.
Featured Stories
- Five stocks we like better than BeOne Medicines
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
